Immuneering and Regeneron Partner to Evaluate IMM-1-104 in RAS-Mutant Lung Cancer

• Immuneering Corporation has entered into a clinical supply agreement with Regeneron Pharmaceuticals to evaluate Libtayo (cemiplimab) in combination with IMM-1-104 for advanced lung cancer.

• The collaboration supports Immuneering’s Phase 2a clinical trial for patients with unresectable or metastatic RAS-mutant non-small cell lung cancer (NSCLC).

Immuneering Corporation (Nasdaq: IMRX) has announced a clinical supply agreement with Regeneron Pharmaceuticals to evaluate the combination of Libtayo (cemiplimab), Regeneron’s anti-PD-1 therapy, with Immuneering’s lead candidate, IMM-1-104, in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer (NSCLC). The combination will be studied as part of Immuneering’s ongoing Phase 2a clinical trial for advanced solid tumors.

The agreement marks the first collaboration for Immuneering involving IMM-1-104. E.B. Brakewood, Chief Business Officer of Immuneering, stated, “Regeneron is a global leader in cancer research and development, and the combination of IMM-1-104 and Libtayo in advanced non-small cell lung cancer has the potential to address unmet needs for patients with this disease.”

Preclinical data previously presented at the Society for Immunotherapy of Cancer (SITC) 2022 annual meeting supports the potential of deep cyclic MEK inhibitors like IMM-1-104 to enhance anti-tumor immunity when combined with PD-1 inhibitors such as Libtayo. Brett Hall, Ph.D., Chief Scientific Officer of Immuneering, noted the drug’s mechanism could help “both break tumor MAPK addiction and enhance anti-tumor immunity.”

Under the terms of the agreement, Immuneering will sponsor the planned studies, while Regeneron will provide Libtayo for the trial. Immuneering retains global development and commercialization rights to IMM-1-104, while Regeneron continues to develop and commercialize Libtayo globally.